Drugs / Risuteganib
Risuteganib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01749891 | Mar 2012 → Jun 2013 | macular degeneration | Allegro Ophthalmics, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01482871 | Jan → Nov 2011 | diabetic macular edema | Allegro Ophthalmics, LLC | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02435862 | Feb 2015 → Aug 2017 | diabetic retinopathy | Allegro Ophthalmics, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02153476 | Feb 2014 → Jun 2015 | vitreous detachment | Allegro Ophthalmics, LLC | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03626636 Comparator | Aug 2017 → Apr 2019 | dry age related macular degeneration | Allegro Ophthalmics, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02348918 Comparator | Oct 2014 → May 2017 | diabetic macular edema | Allegro Ophthalmics, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-25 | AffaMed Therapeutics Limited | Regulatory AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD affamed.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-25 | AffaMed Therapeutics Limited | AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD affamed.com ↗ |
| 2022-01-03 | AffaMed Therapeutics Limited | AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical to Develop and Commercialize Risuteganib (Luminate®) as a First-In-Class Treatment for Intermediate Dry AMD Patients in Greater China affamed.com ↗ |
| 2015-01-13 | Hanmi Pharmaceutical Company Limited | Hanmi pharmaceutical and Allgro Ophthalmics announce strategic investment and collabotation to develop and market LUMINATE? in the Republic Korea and China hanmipharm.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Risuteganib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03626636 ↗ |
| Known as | ALG-1001 | “The general objective of this study is to evaluate the safety and efficacy of ophthalmic intravitreal injections of ALG-1001 in human subjects with wet age-related macular...” NCT01749891 ↗3“Luminate® (ALG-1001) as compared to Avastin® in the Treatment of Diabetic Macular Edema” NCT02348918 ↗ |
| Known as | ALG-1001 HEXAPEPTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297529 ↗ |
| Known as | GLY-ARG-GLY-CYA-THR-PRO | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297529 ↗ |
| Known as | Luminate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02348918 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297529 ↗ |
| Route | Intravitreal | “ophthalmic intravitreal injection” NCT01482871 ↗ |